« Back to Record
Citation APA

Kelley, R. K., Rimassa, L., Cheng, A. L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., Gane, E., Borbath, I., Rangel, J. D. G., Ryoo, B. Y., Makharadze, T., Merle, P., Benzaghou, F., Banerjee, K., Hazra, S., Fawcett, J., & Yau, T. (2022). Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, 23(8), 995-1008. doi:10.1016/S1470-2045(22)00326-6


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/346794

Kelley, R. K., Rimassa, L., Cheng, A. L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., Gane, E., Borbath, I., Rangel, J. D. G., Ryoo, B. Y., Makharadze, T., Merle, P., Benzaghou, F., Banerjee, K., Hazra, S., Fawcett, J., & Yau, T. (2022). Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, 23(8), 995-1008. doi:10.1016/S1470-2045(22)00326-6